Vascular Biogenics (VBLT)
US Market

Vascular Biogenics (VBLT) Stock Price & Analysis


VBLT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.10 - $2.20
Previous Close$0.22
Average Volume (3M)1.20M
Market Cap
Enterprise Value-$10.69M
Total Cash (Recent Filing)$26.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.7
Aug 17, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding70,500,000
10 Day Avg. Volume827,375
30 Day Avg. Volume1,197,175
Standard Deviation0.19
Financial Highlights & Ratios
Price to Book (P/B)0.74
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-19.61
Enterprise Value/Gross Profit-19.30
Enterprise Value/Ebitda0.77
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Vascular Biogenics’s price range in the past 12 months?
Vascular Biogenics lowest stock price was $0.10 and its highest was $2.20 in the past 12 months.
    What is Vascular Biogenics’s market cap?
    Currently, no data Available
    When is Vascular Biogenics’s upcoming earnings report date?
    Vascular Biogenics’s upcoming earnings report date is Aug 17, 2023 which is in 74 days.
      How were Vascular Biogenics’s earnings last quarter?
      Vascular Biogenics released its earnings results on May 15, 2023. The company reported -$0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.034.
        Is Vascular Biogenics overvalued?
        According to Wall Street analysts Vascular Biogenics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Vascular Biogenics pay dividends?
          Vascular Biogenics does not currently pay dividends.
          What is Vascular Biogenics’s EPS estimate?
          Vascular Biogenics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Vascular Biogenics have?
          Vascular Biogenics has 70,500,114 shares outstanding.
            What happened to Vascular Biogenics’s price movement after its last earnings report?
            Vascular Biogenics reported an EPS of -$0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Vascular Biogenics?
              Among the largest hedge funds holding Vascular Biogenics’s share is ARK Investment Management LLC. It holds Vascular Biogenics’s shares valued at N/A.


                Vascular Biogenics Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Vascular Biogenics

                Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Apellis Pharmaceuticals
                Corbus Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis